An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma
暂无分享,去创建一个
Andrew P Stubbs | Winand N M Dinjens | John Turchini | Anthony J Gill | Ozgur Mete | Mauro Papotti | Andrew P. Stubbs | Xavier Matias-Guiu | T. Stephenson | A. Tischler | T. Giordano | M. Smid | M. Papotti | W. Dinjens | E. Korpershoek | S. Asa | A. Gill | R. Lloyd | P. J. van der Spek | X. Matías-Guiu | A. Nigg | F. Tissier | R. D. de Krijger | V. Nosé | L. Erickson | E. Pucci | R. Feelders | A. Stubbs | M. Volante | Ronald R de Krijger | Sylvia L Asa | Thomas J Giordano | Thomas G Papathomas | Marcel Smid | Peter J van der Spek | F. V. van Nederveen | O. Mete | E. Duregon | Lori Erickson | Frédérique Tissier | Eugenio Pucci | Marco Volante | Arthur S Tischler | Esther Korpershoek | Eleonora Duregon | Richard A Feelders | Hao Lu | Ricardo V Lloyd | Francien H van Nederveen | Vania Nose | Kassiani Skordilis | Timothy J Stephenson | Alex Nigg | K. Skordilis | T. Papathomas | J. Turchini | Hao Lu | Eleonora Duregon
[1] M. Papotti,et al. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma , 2014, Modern Pathology.
[2] Toby C. Cornish,et al. Software-automated counting of Ki-67 proliferation index correlates with pathologic grade and disease progression of follicular lymphomas. , 2013, American journal of clinical pathology.
[3] A. Tabarin,et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] T. Giordano. The argument for mitotic rate-based grading for the prognostication of adrenocortical carcinoma. , 2011, The American journal of surgical pathology.
[5] M. Papotti,et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. , 2015, The Journal of clinical endocrinology and metabolism.
[6] A. Zelenetz,et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] A. Hida,et al. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells , 2015, Breast Cancer.
[8] John M S Bartlett,et al. An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.
[9] Harald Frick,et al. How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists , 2012, PloS one.
[10] M. Fassnacht,et al. Update in adrenocortical carcinoma. , 2013, The Journal of clinical endocrinology and metabolism.
[11] V. Adsay. Ki67 Labeling Index in Neuroendocrine Tumors of the Gastrointestinal and Pancreatobiliary Tract: To Count or Not to Count Is Not the Question, But Rather How to Count , 2012, The American journal of surgical pathology.
[12] John M S Bartlett,et al. An international study to increase concordance in Ki67 scoring , 2015, Modern Pathology.
[13] Anais Malpica,et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer , 2012, Histopathology.
[14] T. Miyazaki,et al. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility , 2015, Journal of Clinical Pathology.
[15] Benoît Plancoulaine,et al. A simple way of quantifying immunostained cell nuclei on the whole histologic section , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[16] V. Rousson,et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours , 2006, Histopathology.
[17] Vilppu J Tuominen,et al. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 , 2010, Breast Cancer Research.
[18] A. Gill,et al. Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers. , 2015, The oncologist.
[19] A. Gill,et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. , 2009, Endocrine-related cancer.
[20] N. Kanomata,et al. Assessment of the Ki67 labeling index: a Japanese validation ring study , 2014, Breast Cancer.
[21] T. Giordano,et al. Assessing Biological Aggression in Adrenocortical Neoplasia. , 2014, Surgical pathology clinics.
[22] Michael Goodman,et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies , 2015, Modern Pathology.
[23] Thomas Rüdiger,et al. Inter‐laboratory and inter‐observer reproducibility of immunohistochemical assessment of the Ki‐67 labelling index in a large multi‐centre trial , 2002, The Journal of pathology.
[24] Toby C. Cornish,et al. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. , 2015, American journal of clinical pathology.
[25] Martin Fassnacht,et al. Adrenocortical carcinoma: a clinician's update , 2011, Nature Reviews Endocrinology.
[26] Marco Saerens,et al. Clustering methods applied in the detection of Ki67 hot‐spots in whole tumor slide images: An efficient way to characterize heterogeneous tissue‐based biomarkers , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[27] Andrew P Stubbs,et al. Automated Selection of Hotspots (ASH): enhanced automated segmentation and adaptive step finding for Ki67 hotspot detection in adrenal cortical cancer , 2014, Diagnostic Pathology.
[28] G. Baron,et al. Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors , 2009, Modern Pathology.
[29] G. Kazemier,et al. The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas , 2007, Histopathology.
[30] Jack Cuzick,et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.
[31] H. Tsuda,et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study , 2013, Cancer science.
[32] F. Beuschlein,et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. , 2010, The Journal of clinical endocrinology and metabolism.
[33] Laura H. Tang,et al. Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System: A Comparison of Digital Image Analysis With Manual Methods , 2012, The American journal of surgical pathology.
[34] Laura H. Tang,et al. Effect of Tumor Heterogeneity on the Assessment of Ki67 Labeling Index in Well-differentiated Neuroendocrine Tumors Metastatic to the Liver: Implications for Prognostic Stratification , 2011, The American journal of surgical pathology.
[35] Carsten Denkert,et al. Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study , 2014, Clinical Cancer Research.
[36] M. Papotti,et al. Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. , 2013, Human pathology.